Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia



Rating:

Share or cite this content

Citations should be made in the following way:
J. Huh (Seoul, Republic of Korea), J. Lee (Busan, Republic of Korea), J. Song (Seoul, Republic of Korea). Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis. 468

Member's Comments

No comment yet.

Related content which might interest you: Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis Source: Eur Respir J, 52 (2) 1800230; 10.1183/13993003.00230-2018 Year: 2018 Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2006; 28: Suppl. 50, 767s Year: 2006 Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1382-1392 Year: 2015 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Long-term efficacy and safety of N-acetylcysteine inhalation in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias Year: 2018 Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA Source: Eur Respir J, 52 (1) 1702106; 10.1183/13993003.02106-2017 Year: 2018 A prosprective study on the safety, tolerability and efficacy of pirfinidone in the treatment of idiopathic pulmonary fibrosis and fibrotic NSIP Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis Year: 2012 Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 58-64 Year: 2015 Treatment efficacy of idiopathic pulmonary fibrosis depending on the dose difference of pirfenidone Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Efficacy and tolerability of nintedanib switched from pirfenidone for IPF patients Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Characteristics and management of patients with idiopathic pulmonary fibrosis treated with pirfenidone capsule or tablet formulation Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018 Year: 2018 Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Source: Eur Respir J 2016; 48: 843-851 Year: 2016 Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation Source: Eur Respir J, 57 (2) 2003198; 10.1183/13993003.03198-2020 Year: 2021